Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoved the site-wide government funding status notice; this change does not affect the study details, eligibility criteria, or results presented on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedPosted results and updated outcome measures are now on the page for NCT05817669, including primary and secondary outcomes and safety data, with the Results First Posted date of 2025-07-18.SummaryDifference0.4%

- Check62 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. The page now communicates operating status details and a newer software version.SummaryDifference3%

- Check69 days agoChange DetectedAdded version update to v3.1.0 and removed several topic headings (MedlinePlus drug safety topics and an older v3.0.2), indicating a reorganization and upgrade rather than new substantive content.SummaryDifference0.5%

- Check84 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed.SummaryDifference0.2%

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.